Testing exosomes during treatment for rectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial studies “exosomes” (tiny cell signals being researched as a possible way to affect cancer treatment) in people with rectal cancer. You would receive standard chemotherapy plus radiation before planned surgery, and the trial looks at outcomes related to that treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 years old or older
- Have rectal adenocarcinoma confirmed by pathology (a lab test on tissue)
- Plan to start chemotherapy plus radiation before your scheduled rectal surgery
- Be willing and able to undergo definitive rectal surgery
- Do not have a history of radiation or chemotherapy to the pelvis/rectal area before (including pelvic external beam radiation, brachytherapy, or prior chemotherapy)
- Have not had other cancers before (except non-melanoma skin cancers) and not be immunocompromised
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a short course of radiation before surgery, combined with the immunotherapy drug envafolimab and the chemo regimen CAPEOX, works better for shrinking locally advanced rectal cancer. It is aimed at people whose tumor is not “MMR-deficient” (it is pMMR/MSS), and it asks participants to be able to return for repeated checkups and treatments.
This study looks at how rectal cancer responds to the usual chemotherapy and radiation given before surgery. It aims to learn if certain molecular features of your tumor can predict how well it responds to treatment.
This trial tests a new treatment sequence for locally advanced rectal cancer: a short course of radiation followed by a combination of immunotherapy (cadonilimab) and chemotherapy (mFOLFOX6) before surgery. The goal is to shrink the tumor more effectively and potentially improve outcomes.
This trial tests a new approach for people with locally advanced rectal cancer that has high-risk features. It combines short-course radiation with chemotherapy (CapeOX) and the immunotherapy drug toripalimab, with or without another drug called surufatinib, before surgery. The goal is to see if adding these drugs helps shrink the tumor and improve outcomes.
This trial tests a combination of chemotherapy and radiation therapy before surgery for people with mid or low rectal cancer that hasn't spread. The goal is to see if this approach works better than current treatments.
This trial tests a combination of short-course radiation, chemotherapy (CapeOx), and an immunotherapy drug (PD-1 inhibitor) for people with early-stage rectal cancer who have had a local excision but are at high risk of the cancer coming back. The goal is to avoid more extensive surgery while still effectively treating the cancer.
Hear when a new Rectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.